Passive income is the paycheck that arrives whether you show up or not. Wages depend on a functioning employer, a healthy ...

Lupin has received tentative approval from the Food and Drug Administration for enzalutamide tablets, 40 mg, 80 mg, 120 mg and 160 mg. Xtandi is used to treat certain types of pro ...

By Michael Erman and Deena Beasley NEW YORK/SAN DIEGO, June 30 (Reuters) - President Donald Trump has promised to make U.S.

Four industry lobbyists said that based on feedback from pharmaceutical companies, mid-sized and smaller drugmakers have not ...

A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...

The company also experienced a recent setback with sigvotatug vedotin failing to meet the primary endpoint in a phase 3 study targeting previously treated non-small cell lung cancer (NSCLC). There's ...

Lupin rose 2.21% to Rs 2,393.80 after it has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets in ...

Lupin's shares rose as the USFDA granted tentative approval for its Enzalutamide tablets, offering new dosing options alongside bioequivalent alternatives to Xtandi.

The USFDA has tentatively approved the 40 mg and 80 mg strengths as bioequivalent to Xtandi Tablets of Astellas.

The sizable yield comes with a concerning footnote. Just look at the rest of the story.

The U.S. FDA has tentatively approved Lupin's Enzalutamide Tablets, 40 mg and 80 mg as bioequivalent to reference listed drug (RLD) Xtandi® Tablets of Astellas for the indication in the approved ...

Lupin Limited has received tentative approval from the FDA for its abbreviated new drug application (ANDA) for enzalutamide ...